The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma

Angela Franciska Haczku, Andrew Alexander, Peter Brown, Basil Assoufi, Baiqing Li, A. Barry Kay, Christopher Corrigan

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Inhibition of T-lymphocyte activation may provide a useful approach to the treatment of chronic severe asthma. We compared rapamycin, a novel immunosuppressive drug, with cyclosporine and dexamethasone for its effects in inhibiting proliferation of T lymphocytes from patients with glucocorticoid-resistant and glucocorticoid-sensitive asthma. Phytohemagglutinin-stimulated peripheral blood T lymphocytes from 11 patients with clinically glucocorticoid-resistant and 8 patients with glucocorticoid-sensitive chronic asthma were tested for sensitivity to these drugs in a highly reproducible proliferation assay. All drugs inhibited proliferation in a dose-dependent manner (10-6 to 10-10 mol/L). T lymphocytes from the patients with glucocorticoid-resistant asthma were significantly less sensitive (p < 0.01) to dexamethasone than those of patients with glucocorticoid-sensitive asthma over a wide concentration range. In contrast, cyclosporine and rapamycin inhibited cells from both patient groups to an equivalent extent. The presence of exogenous interleukin-2 abrogated the inhibitory effect of dexamethasone but not that of cyclosporine or rapamycin, suggesting that dexamethasone may act principally by inhibition of interleukin-2 production, whereas the latter drugs exert distinct or additional inhibitory effects. Stimulation of peripheral blood T lymphocytes with phytohemagglutinin for 24 hours before addition of the drugs abolished the inhibitory effect of dexamethasone and significantly reduced that of cyclosporine. The inhibitory effect of rapamycin was, however, unaltered. These data suggest that dexamethasone and cyclosporine exert their effects only at an early stage of T-lymphocyte activation, whereas rapamycin is able to inhibit lymphoblasts. The fact that the inhibitory mechanisms of these drugs are different might explain why cyclosporine and rapamycin are effective in inhibiting T lymphocytes from both patients with glucocorticoid-sensitive and those with glucocorticoid-resistant asthma. The data further suggest that cyclosporine and rapamycin may be effective for the therapy of glucocorticoid-resistant asthma.

Original languageEnglish (US)
Pages (from-to)510-519
Number of pages10
JournalThe Journal of Allergy and Clinical Immunology
Volume93
Issue number2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Sirolimus
Dexamethasone
Cyclosporine
Glucocorticoids
Asthma
T-Lymphocytes
Pharmaceutical Preparations
Phytohemagglutinins
Lymphocyte Activation
Interleukin-2
In Vitro Techniques
Immunosuppressive Agents
Therapeutics

Keywords

  • Asthma
  • glucocorticoid resistance
  • immunosuppressants
  • T lymphocytes
  • therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro : Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma. / Haczku, Angela Franciska; Alexander, Andrew; Brown, Peter; Assoufi, Basil; Li, Baiqing; Kay, A. Barry; Corrigan, Christopher.

In: The Journal of Allergy and Clinical Immunology, Vol. 93, No. 2, 1994, p. 510-519.

Research output: Contribution to journalArticle

@article{26ce425eb7684887bcf962350848edd2,
title = "The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma",
abstract = "Inhibition of T-lymphocyte activation may provide a useful approach to the treatment of chronic severe asthma. We compared rapamycin, a novel immunosuppressive drug, with cyclosporine and dexamethasone for its effects in inhibiting proliferation of T lymphocytes from patients with glucocorticoid-resistant and glucocorticoid-sensitive asthma. Phytohemagglutinin-stimulated peripheral blood T lymphocytes from 11 patients with clinically glucocorticoid-resistant and 8 patients with glucocorticoid-sensitive chronic asthma were tested for sensitivity to these drugs in a highly reproducible proliferation assay. All drugs inhibited proliferation in a dose-dependent manner (10-6 to 10-10 mol/L). T lymphocytes from the patients with glucocorticoid-resistant asthma were significantly less sensitive (p < 0.01) to dexamethasone than those of patients with glucocorticoid-sensitive asthma over a wide concentration range. In contrast, cyclosporine and rapamycin inhibited cells from both patient groups to an equivalent extent. The presence of exogenous interleukin-2 abrogated the inhibitory effect of dexamethasone but not that of cyclosporine or rapamycin, suggesting that dexamethasone may act principally by inhibition of interleukin-2 production, whereas the latter drugs exert distinct or additional inhibitory effects. Stimulation of peripheral blood T lymphocytes with phytohemagglutinin for 24 hours before addition of the drugs abolished the inhibitory effect of dexamethasone and significantly reduced that of cyclosporine. The inhibitory effect of rapamycin was, however, unaltered. These data suggest that dexamethasone and cyclosporine exert their effects only at an early stage of T-lymphocyte activation, whereas rapamycin is able to inhibit lymphoblasts. The fact that the inhibitory mechanisms of these drugs are different might explain why cyclosporine and rapamycin are effective in inhibiting T lymphocytes from both patients with glucocorticoid-sensitive and those with glucocorticoid-resistant asthma. The data further suggest that cyclosporine and rapamycin may be effective for the therapy of glucocorticoid-resistant asthma.",
keywords = "Asthma, glucocorticoid resistance, immunosuppressants, T lymphocytes, therapy",
author = "Haczku, {Angela Franciska} and Andrew Alexander and Peter Brown and Basil Assoufi and Baiqing Li and Kay, {A. Barry} and Christopher Corrigan",
year = "1994",
doi = "10.1016/0091-6749(94)90361-1",
language = "English (US)",
volume = "93",
pages = "510--519",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro

T2 - Comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma

AU - Haczku, Angela Franciska

AU - Alexander, Andrew

AU - Brown, Peter

AU - Assoufi, Basil

AU - Li, Baiqing

AU - Kay, A. Barry

AU - Corrigan, Christopher

PY - 1994

Y1 - 1994

N2 - Inhibition of T-lymphocyte activation may provide a useful approach to the treatment of chronic severe asthma. We compared rapamycin, a novel immunosuppressive drug, with cyclosporine and dexamethasone for its effects in inhibiting proliferation of T lymphocytes from patients with glucocorticoid-resistant and glucocorticoid-sensitive asthma. Phytohemagglutinin-stimulated peripheral blood T lymphocytes from 11 patients with clinically glucocorticoid-resistant and 8 patients with glucocorticoid-sensitive chronic asthma were tested for sensitivity to these drugs in a highly reproducible proliferation assay. All drugs inhibited proliferation in a dose-dependent manner (10-6 to 10-10 mol/L). T lymphocytes from the patients with glucocorticoid-resistant asthma were significantly less sensitive (p < 0.01) to dexamethasone than those of patients with glucocorticoid-sensitive asthma over a wide concentration range. In contrast, cyclosporine and rapamycin inhibited cells from both patient groups to an equivalent extent. The presence of exogenous interleukin-2 abrogated the inhibitory effect of dexamethasone but not that of cyclosporine or rapamycin, suggesting that dexamethasone may act principally by inhibition of interleukin-2 production, whereas the latter drugs exert distinct or additional inhibitory effects. Stimulation of peripheral blood T lymphocytes with phytohemagglutinin for 24 hours before addition of the drugs abolished the inhibitory effect of dexamethasone and significantly reduced that of cyclosporine. The inhibitory effect of rapamycin was, however, unaltered. These data suggest that dexamethasone and cyclosporine exert their effects only at an early stage of T-lymphocyte activation, whereas rapamycin is able to inhibit lymphoblasts. The fact that the inhibitory mechanisms of these drugs are different might explain why cyclosporine and rapamycin are effective in inhibiting T lymphocytes from both patients with glucocorticoid-sensitive and those with glucocorticoid-resistant asthma. The data further suggest that cyclosporine and rapamycin may be effective for the therapy of glucocorticoid-resistant asthma.

AB - Inhibition of T-lymphocyte activation may provide a useful approach to the treatment of chronic severe asthma. We compared rapamycin, a novel immunosuppressive drug, with cyclosporine and dexamethasone for its effects in inhibiting proliferation of T lymphocytes from patients with glucocorticoid-resistant and glucocorticoid-sensitive asthma. Phytohemagglutinin-stimulated peripheral blood T lymphocytes from 11 patients with clinically glucocorticoid-resistant and 8 patients with glucocorticoid-sensitive chronic asthma were tested for sensitivity to these drugs in a highly reproducible proliferation assay. All drugs inhibited proliferation in a dose-dependent manner (10-6 to 10-10 mol/L). T lymphocytes from the patients with glucocorticoid-resistant asthma were significantly less sensitive (p < 0.01) to dexamethasone than those of patients with glucocorticoid-sensitive asthma over a wide concentration range. In contrast, cyclosporine and rapamycin inhibited cells from both patient groups to an equivalent extent. The presence of exogenous interleukin-2 abrogated the inhibitory effect of dexamethasone but not that of cyclosporine or rapamycin, suggesting that dexamethasone may act principally by inhibition of interleukin-2 production, whereas the latter drugs exert distinct or additional inhibitory effects. Stimulation of peripheral blood T lymphocytes with phytohemagglutinin for 24 hours before addition of the drugs abolished the inhibitory effect of dexamethasone and significantly reduced that of cyclosporine. The inhibitory effect of rapamycin was, however, unaltered. These data suggest that dexamethasone and cyclosporine exert their effects only at an early stage of T-lymphocyte activation, whereas rapamycin is able to inhibit lymphoblasts. The fact that the inhibitory mechanisms of these drugs are different might explain why cyclosporine and rapamycin are effective in inhibiting T lymphocytes from both patients with glucocorticoid-sensitive and those with glucocorticoid-resistant asthma. The data further suggest that cyclosporine and rapamycin may be effective for the therapy of glucocorticoid-resistant asthma.

KW - Asthma

KW - glucocorticoid resistance

KW - immunosuppressants

KW - T lymphocytes

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=0028289245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028289245&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(94)90361-1

DO - 10.1016/0091-6749(94)90361-1

M3 - Article

C2 - 8120277

AN - SCOPUS:0028289245

VL - 93

SP - 510

EP - 519

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 2

ER -